IDNAiShares Genomics Immunology and Healthcare ETF

Grow my money7y track recordRanked #1,080 of 2,960 in this goal

Seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from growth in genomics.

By iShares · Launched 2019

Annual Cost

0.47%

#2,305 of 5,562 · average

Fund Size

$163M

#2,472 of 5,562 · mid-size

Return (1Y)Goal

+50.4%

Track Record

7 years

#1,926 of 5,562 · seasoned

Performance

Total-return NAV · USD

Growth of $10,000

$15,108+51.1%

Total-return NAV, USD. Net of fund fees, before tax.

Classification

How Beacon categorizes this fund

Asset class

Equity

Region

Global

Cap

Multi cap

Strategy

Index tracking

Sector

Health care

Focus

Biotech & Genomics

Index tracked

NYSE FactSet Global Genomics and Immuno Biopharma Index

What it actually holds

By weight

Concentration

Top 10 holdings = 57.4% of fundmoderately concentrated

BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares

16.5%

MODERNA, INC.

5.9%

Bayer Aktiengesellschaft

5.0%

Revolution Medicines Inc

4.5%

Takeda Pharmaceutical Company Limited

4.4%

BioNTech SE

4.4%

Roche Holding AG

4.3%

IPSEN SA

4.3%

MERCK & CO., INC.

4.1%

GSK PLC

4.0%

Asset allocation

Stocks

99.6%

Cash

0.4%

By sector

Healthcare

100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

24.9%High

Year-on-year price swings

Max drawdown

-68.3%Severe

Worst peak-to-trough loss

Sharpe (3Y)

0.31Below average

Sortino (3Y)

0.45Moderate downside risk

Where to buy

Listing

Exchange: NYSE Arca

Full fund details

Objective: Seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from growth in genomics.
Strategy: Tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index, which measures equity securities from companies in biopharmaceutical and healthcare industries. The Fund invests primarily in companies with significant revenue from genomics and immunology, selected based on a composite score. It generally invests at least 80% of assets in index components and may use representative sampling.
Inception date: June 11, 2019
Fund family: iShares